ON
← Nazaj na pregled
Nova pot do hujšanja? Odkrili beljakovino, ki hkrati kuri in preprečuje maščobo
Slovenia🏛️ Politikavčeraj

Nova pot do hujšanja? Odkrili beljakovino, ki hkrati kuri in preprečuje maščobo

Scientists from the Weizmann Institute discovered a biological mechanism involving the protein MTCH2 (called 'Mitch') that could potentially lead to new treatments for obesity. The research, published in the journal EMBO Journal, showed that disabling Mitch increases fat burning, boosts energy expenditure, and inhibits the creation of new fat cells. Experiments on mice revealed that those lacking Mitch were leaner, had more muscle fibers, and exhibited greater endurance. Further tests on human cells confirmed that removing Mitch caused cells to burn significantly more energy, primarily from fats. Analysis indicated increased cellular respiration and faster breakdown of fats, carbohydrates, and amino acids. Mitch was also found to influence both fat consumption and fat cell production—its removal slowed the development of fat cells by reducing their energy and materials. Lead researcher Professor Atan Gross suggested that blocking Mitch could represent a novel approach to treating obesity by accelerating fat burning while preserving or improving muscle mass. While the findings are preliminary and based on cell cultures and mouse models, they offer promising insights into metabolism.

Kako je poročala vsaka stran

Isti dogodek, razvrščen po političnem nagibu medijev, ki so o njem poročali.

Kako je poročala vsaka stran

Podprite neodvisne novice z zavedanjem pristranskosti in odklenite družbeni utrip, glasovanje skupnosti in svoj prilagojen pregled Zame.

Postani podpornik

Poročanje po svetu

Isti dogodek, kot so ga poročali v drugih državah.

Poročanje po svetu

Podprite neodvisne novice z zavedanjem pristranskosti in odklenite družbeni utrip, glasovanje skupnosti in svoj prilagojen pregled Zame.

Postani podpornik

Preverjanje trditev

Ključne dejanske trditve in koliko virov jih potrjuje oz. zavrača.

Preverjanje trditev

Podprite neodvisne novice z zavedanjem pristranskosti in odklenite družbeni utrip, glasovanje skupnosti in svoj prilagojen pregled Zame.

Postani podpornik

1 poročil

Delo logoDeloNeodvisen🔒SredinaDejstva 95Objektivnost 85včeraj
Nova pot do hujšanja? Odkrili beljakovino, ki hkrati kuri in preprečuje maščobo

Scientists from the Weizmann Institute discovered a biological mechanism involving the protein MTCH2 (called 'Mitch') that could potentially lead to new treatments for obesity. The research, published in the journal EMBO Journal, showed that disabling Mitch increases fat burning, boosts energy expenditure, and inhibits the creation of new fat cells. Experiments on mice revealed that those lacking Mitch were leaner, had more muscle fibers, and exhibited greater endurance. Further tests on human cells confirmed that removing Mitch caused cells to burn significantly more energy, primarily from fats. Analysis indicated increased cellular respiration and faster breakdown of fats, carbohydrates, and amino acids. Mitch was also found to influence both fat consumption and fat cell production—its removal slowed the development of fat cells by reducing their energy and materials. Lead researcher Professor Atan Gross suggested that blocking Mitch could represent a novel approach to treating obesity by accelerating fat burning while preserving or improving muscle mass. While the findings are preliminary and based on cell cultures and mouse models, they offer promising insights into metabolism.

Ocena pristranskosti (Sredina): The article presents scientific research without overt ideological framing. It discusses medical discoveries and their potential implications for health treatment, focusing on factual outcomes rather than political agendas. The tone remains neutral, emphasizing the scientific process and future drug

Zakaj te ocene (Dejstva 95 · Objektivnost 85): The article presents a detailed summary of the research findings accurately, citing the institute, journal, and methodology. It clearly states that the discovery is in early stages and not yet a drug. The information aligns with cross-source consensus, though some technical details may be simplified

Ohranimo novice poštene.

ObjectiveNews financirajo bralci in je brez oglasov – pristranskost vam pokažemo, ne skrijemo. Podprite neodvisno novinarstvo za 5 €/mesec.

Postani podpornik

Povezane zgodbe